November 2015
U.S. Dept. of Health and Human Services. Office of the Secretary. Office of the Assistant Secretary for Planning and Evaluation and Office of Minority Health
About This Report
Office of Science and Data Policy (SDP)
The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.
The Office of Science and Data Policy includes several components:
- Division of Science and Public Health Policy
- Division of Evidence, Evaluation and Data Policy
- Division of Strategic Planning
Topic Areas:
- HHS Data Council
- Regulatory Impact Analysis
- Strategic Planning
- Information Quality Guidelines
- Prevention and wellness
- Public health systems and functions
- Food safety and nutrition
- Drugs and devices
- Tobacco control and prevention
- Biomedical research and development
- Economic analysis
- Emergency preparedness, response, and recovery
- Data and statistical policy
- Health disparities and vulnerable populations
- Health information technology
- Microsimulation
- Privacy policy
Reports
Displaying 81 - 90 of 158. 10 per page. Page 9.
Advanced SearchValuing Utility Offsets to Regulations Affecting Addictive or Habitual Goods
In analyzing the value consumers place on goods, economic analysis begins with the presumption that consumers reveal their preferences through their consumption behavior. This view is based on the notion that consumers are well informed and well situated to rationally balance the costs and benefits of purchasing a specific good or service.
Minimizing Disclosure Risk in HHS Open Data Initiatives
Federal agencies have a long history of releasing data to the public, and they also have a legal obligation to protect the confidentiality of the individuals and organizations from which the data were collected. Federal agencies have successfully balanced these two objectives for decades.
Examination of Clinical Trial Costs and Barriers for Drug Development
Pharmaceutical companies conduct clinical trials for many reasons. The most obvious goal of clinical trials is to demonstrate safety and efficacy to gain Food and Drug Administration (FDA) approval. FDA provides guidance to developers about what constitutes acceptable clinical trials and appropriate outcomes.
Analytical Framework for Examining the Value of Antibacterial Products
Antibacterial resistance is a growing global problem. At least 2 million people in the U.S. acquire serious infections with bacteria that are resistant to one or more of antibacterial drugs designed to treat it.
Rapid Evaluation Approaches for Complex Initiatives
This paper presents a comparative framework of rapid evaluation methods for projects of three levels of complexity: quality improvement methods for simple process improvement projects; rapid cycle evaluations for complicated organizational change programs, and systems-based rapid feedback methods for large-scale systems change or population change initiatives.
Understanding Disparities in Persons with Multiple Chronic Conditions: Research Approaches and Datasets
Final White Paper Contract # HHSP2333700IT Prepared for: James Sorace, MD, MS, Michael Millman, PhD Assistant Secretary for Planning and Evaluation U.S. Department of Health & Human Services 200 Independence Ave. S.W. Washington, DC 20201